<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48434">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02475681</url>
  </required_header>
  <id_info>
    <org_study_id>ACE-CL-007</org_study_id>
    <nct_id>NCT02475681</nct_id>
  </id_info>
  <brief_title>Elevate CLL TN: Study of Obinutuzumab + Chlorambucil, Acalabrutinib (ACP-196) + Obinutuzumab, and Acalabrutinib in Subjects With Previously Untreated CLL</brief_title>
  <official_title>A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, Acalabrutinib (ACP-196) in Combination With Obinutuzumab, and Acalabrutinib Monotherapy in Subjects With Previously Untreated CLL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acerta Pharma BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acerta Pharma BV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is evaluating the efficacy of obinutuzumab in combination with chlorambucil
      compared with acalabrutinib in combination with obinutuzumab (Arm B) for the treatment of
      previously untreated chronic lymphocytic leukemia (CLL).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2015</start_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival in Arm A compared to Arm B</measure>
    <time_frame>49 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>IRC-assessed objective response rate (ORR) in Arm A versus Arm B and Arm A versus Arm C</measure>
    <time_frame>49 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next treatment (TTNT) in Arm A versus Arm B and Arm A versus Arm C</measure>
    <time_frame>49 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events, serious adverse events and changes in laboratory measurements in Arm A versus Arm B and Arm A versus Arm C</measure>
    <time_frame>49 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival in Arm A versus Arm B and Arm A versus Arm C</measure>
    <time_frame>49 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">535</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Obinutuzumab in Combination with Chlorambucil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Obinutuzumab IV infusions will be administered over a total of 6 treatment cycles. Chlorambucil will be orally administered on Days 1 and 15 of Cycles 1 through 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acalabrutinib in Combination with Obinutuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Obinutuzumab IV infusions will be administered over a total of 6 treatment cycles. ACP-196 will be orally administered starting on Cycle 1 Day 1. Daily administration of ACP-196 will continue until disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acalabrutinib Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acalabrutinib will be orally administered on Cycle 1 Day 1 until disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acalabrutinib</intervention_name>
    <arm_group_label>Acalabrutinib in Combination with Obinutuzumab</arm_group_label>
    <arm_group_label>Acalabrutinib Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <arm_group_label>Obinutuzumab in Combination with Chlorambucil</arm_group_label>
    <arm_group_label>Acalabrutinib in Combination with Obinutuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorambucil</intervention_name>
    <arm_group_label>Obinutuzumab in Combination with Chlorambucil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women: ≥ 65 years of age OR &gt; 18 and &lt; 65 years of age, provided that they
             meet at least one of the following criteria:

               1. Creatinine clearance 30 to 69 mL/min.

               2. A score higher than 6 on the Cumulative Illness Rating Scale-Geriatric.

          -  ECOG performance status of 0, 1, or 2.

          -  Diagnosis of CD20+ CLL.

          -  Active disease meeting ≥ 1 of the following IWCLL 2008 criteria for requiring
             treatment.

          -  Meet the following laboratory parameters:

               1. ANC ≥ 750 cells/μL, or ≥ 500 cells/μL in subjects with documented bone marrow
                  involvement, and independent of growth factor support 7 days before assessment.

               2. Platelet count ≥ 50,000 cells/μL, or ≥ 30,000 cells/μL in subjects with
                  documented bone marrow involvement, and without transfusion support 7 days
                  before assessment. Subjects with transfusion-dependent thrombocytopenia are
                  excluded.

               3. Serum AST and ALT/SGPT ≤ 3.0 x ULN.

               4. Total bilirubin ≤ 1.5 x ULN.

               5. Estimated creatinine clearance ≥ 30 mL/min.

        Exclusion Criteria:

          -  Any prior systemic treatment for CLL.

          -  Known CNS lymphoma or leukemia.

          -  Known prolymphocytic leukemia or history of, or currently suspected, Richter's
             syndrome.

          -  Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura.

          -  Major surgery within 4 weeks before first dose of study drug.

          -  Prior malignancy, except for adequately treated lentigo maligna melanoma,
             non-melanomatous skin cancer, in situ cervical carcinoma, or other malignancy treated
             with no evidence of active disease &gt; 3 years before Screening and at low risk for
             recurrence.

          -  Significant cardiovascular disease within 6 months of screening.

          -  Known history of infection with HIV.

          -  History of stroke or intracranial hemorrhage within 6 months before randomization.

          -  Known history of a bleeding diathesis.

          -  Requires or receiving anticoagulation with warfarin or equivalent vitamin K
             antagonists within 7 days of first dose of study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Priti Patel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Acerta Pharma BV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Oncology Associates</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Cancer Medical Center Inc.</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Specialists</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology, P.A.</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Institute and Research Center</name>
      <address>
        <city>Springfield</city>
        <state>Oregon</state>
        <zip>97477</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Medical City Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Dallas Presbyterian Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Centers of South Texas</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Centers of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Deke Slayton Cancer Center</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of Southwest Virginia, Inc.</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yakima Valley Memorial Hospital / North Star Lodge</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 14, 2017</lastchanged_date>
  <firstreceived_date>June 12, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obinutuzumab</mesh_term>
    <mesh_term>Chlorambucil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
